FOR UK HEALTHCARE PROFESSIONALS ONLY
For UK Healthcare Professionals Only

Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

  1. Home
  2. Atopic dermatitis
  3. Real-world experience

Real-world experience in UK centres

  • Manchester (Salford): A retrospective review at 3 and 6 months of records from 164 adult patients (≥18 years) with moderate-to-severe atopic dermatitis (AD) treated with DUPIXENT2
  • Specialist eczema clinic: A prospective 52-week observational cohort of 100 adult patients (≥18 years) with moderate-to-severe AD treated with DUPIXENT3

Reimbursement

Learn about the reimbursement of DUPIXENT.

Find out more

Safety profile

Learn more about the safety profile of DUPIXENT.

Find out more

Dosing

Learn more about how to administer DUPIXENT.

Find out more

AD, atopic dermatitis; UK, United Kingdom.

References

  1. DUPIXENT Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8553/smpc. Date accessed: July 2021.
  2. Kreeshan FC, et al. Dermatol Ther (Heidelb). 2021;11(1):149–160.
  3. Sears AV, et al. Br J Dermatol. 2021;184(4):755–757.